OBJECTIVES: Intravenous (iv) infusion of biologic agents is a highly effective therapeutic option in treating active Rheumatoid Arthritis (RA) patients. In Greece, it is mandatory that all infusions are administered in a hospital setting, therefore, they are strongly correlated with the system’s capacity in terms of resources. The objective of this study was to assess the capacity of the Greek National Health System (NHS) hospitals to meet current and projected demand for the iv treatment of RA patients. METHODS: Semi-qualitative interviews on the basis of a strictly structured questionnaire were conducted with the Heads of all NHS RA infusion sites, to record available resources (staff, equipment, facilities), service utilization and ability to meet current and projected demand. The questionnaire was externally reviewed and piloted to a small sample before administration. Data were analyzed using SPSSv15.0. RESULTS: From a total of 31 NHS infusion sites (rheumatology clinics, outpatient departments, pathology clinics, day clinics), 28 responded (Response Rate 90.3%). On average, 41.6% of Greek NHS RA patients are treated with a biologic agent. 64.2% of respondents stated that available resources are insufficient to meet current demand. The most important constraints in selection order were: space (92.8%), staff (89.2%), equipment (iv-pumps, beds and chairs - 64.2%) and working hours (60.7%). A total of 56% of respondents stated that they may decline treatment to patients due to capacity constraints. Overall, respondents estimated that the number of iv patients could be increased by 104% on average, were there no capacity constraints. CONCLUSIONS: An important proportion of the estimated 40.000 RA patients in Greece, for whom iv biologic treatment in the hospital setting is essential for disease control, may be declined treatment due to constraints in RA-specific resources. Rationalization and reallocation of NHS resources is required to ensure equity in access to effective treatment for all RA patients.